---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-25-000010"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:26:49.530659+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Autolus reports FY2024 net loss $220.7M; AUCATZYL launch on track with 33 U.S. centers

## Summary
- Net loss $220.7M ($0.86 per share) vs $208.4M ($1.20) in 2023; revenue $10.1M (up from $1.7M).
- Cash and marketable securities $588M at Dec 31, 2024, up from $239.6M, boosted by BioNTech deal and equity financing.
- AUCATZYL commercial launch: 33 authorized treatment centers (covering ~60% of target U.S. patients); targeting 60 by end-2025.
- Obe-cel under EMA/MHRA review with decisions expected H2 2025; Phase 1 SLE trial fully enrolled (6 patients), data at April R&D event.
- BioNTech option for AUTO1/22 expired Feb 8, 2025, not exercised; Blackstone $30M milestone payment triggered by FDA approval.

## SEC filing metadata
- accession: 0001730463-25-000010
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046325000010/0001730463-25-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046325000010/autl-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-25-000010
- JSON: https://secwatch.observer/filing/0001730463-25-000010.json
- Plain text: https://secwatch.observer/filing/0001730463-25-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.